Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	182 men with chronic bacterial prostatitis	Gastrointestinal disorders 5/93 (5%) with lomefloxacin 400 mg daily for 4 weeks 8/89 (9%) with ciprofloxacin 500 mg twice daily for 4 weeks	Significance not assessed
RCT	182 men with chronic bacterial prostatitis	Premature withdrawal from the study because of adverse effects 5/93 (5%) with lomefloxacin 400 mg daily for 4 weeks 4/89 (4%) with ciprofloxacin 500 mg twice daily for 4 weeks	Significance not assessed
RCT	377 men with chronic bacterial prostatitis	At least 1 treatment-related adverse effect 87/197 (44%) with levofloxacin 500 mg daily for 28 days 67/180 (37%) with ciprofloxacin 500 mg twice daily for 28 days	Significance not assessed
RCT	377 men with chronic bacterial prostatitis	Gastrointestinal disturbances 19% with levofloxacin 500 mg daily for 28 days 17% with ciprofloxacin 500 mg twice daily for 28 days Absolute numbers not reported	Significance not assessed
RCT	96 men with chronic bacterial prostatitis	Adverse effects 6 months after treatment completion 8/44 (18%) with prulifloxacin 600 mg daily for 4 weeks 10/45 (22%) with levofloxacin 500 mg daily for 4 weeks	P = 0.79		Not significant
RCT	63 men with prostate infection caused by Ureaplasma urealyticum	Nausea 5/32 (15%) with doxycycline 100 mg twice daily for 3 weeks no data reported with placebo